Soichiro Ogawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Soichiro Ogawa has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
Junya Hata
Department of Urology, Fukushima Medical University School of Medicine, Fukushima
22 shared publicationsYoshiyuki Kojima
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan
22 shared publicationsYuichi Sato
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan
22 shared publicationsHidenori Akaihata
Department of Urology, Fukushima Medical University School of Medicine, Fukushima
19 shared publicationsKei Ishibashi
Department of Urology Fukushima Medical University School of Medicine Fukushima Japan
14 shared publicationsMasao Kataoka
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan
14 shared publications
Latest Publications
- 23 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10)
Maternal Parenting Styles and Nighttime Diaper Use in Early Childhood: The Japan Environment and Children's Study
Purpose: To examine cross‐sectional and longitudinal associations between maternal parenting style and nighttime diaper use in early childhood. Methods: We analyzed data from the Japan Environment and Children's Study, a nationwide prospective birth cohort. Maternal parenting styles were categorized as Authoritative, Authoritarian, Permissive, or Uninvolved using responsiveness and demandingness scores from a validated parenting attitude questionnaire. Nighttime diaper use was assessed at ages 3 and 4 years. Multivariable modified Poisson regression with robust error variance was applied to estimate adjusted prevalence ratios (aPRs) for nighttime diaper use at age 3 and adjusted risk ratios (aRRs) for its persistence from ages 3 to 4. Results: The cross‐sectional and longitudinal analyses included 65 765 and 54 915 mother–child pairs, respectively. Compared with the Uninvolved style, aPRs for nighttime diaper use at age 3 were 0.96 (95% CI, 0.95–0.97) for Authoritative, 0.99 (95% CI, 0.98–1.00) for Authoritarian, and 0.99 (95% CI, 0.99–1.00) for Permissive styles. The corresponding aRRs for persistent nighttime diaper use were 0.93 (95% CI, 0.91–0.95), 0.96 (95% CI, 0.94–0.98), and 0.98 (95% CI, 0.96–1.01). No significant interaction was found with child sex, whereas a significant interaction was observed between child developmental status and Authoritarian style. Conclusions: Maternal parenting styles were associated with nighttime diaper use at age 3 and its persistence at age 4. Although nighttime diaper use is not a direct measure of nocturnal continence, these findings suggest that maternal caregiving context may be relevant to early nighttime diaper discontinuation before school age. Trial Registration: ClinicalTrials.gov identifier: UMIN000030786
- 23 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10)
Maternal Parenting Styles and Nighttime Diaper Use in Early Childhood: The Japan Environment and Children's Study
Purpose: To examine cross‐sectional and longitudinal associations between maternal parenting style and nighttime diaper use in early childhood. Methods: We analyzed data from the Japan Environment and Children's Study, a nationwide prospective birth cohort. Maternal parenting styles were categorized as Authoritative, Authoritarian, Permissive, or Uninvolved using responsiveness and demandingness scores from a validated parenting attitude questionnaire. Nighttime diaper use was assessed at ages 3 and 4 years. Multivariable modified Poisson regression with robust error variance was applied to estimate adjusted prevalence ratios (aPRs) for nighttime diaper use at age 3 and adjusted risk ratios (aRRs) for its persistence from ages 3 to 4. Results: The cross‐sectional and longitudinal analyses included 65 765 and 54 915 mother–child pairs, respectively. Compared with the Uninvolved style, aPRs for nighttime diaper use at age 3 were 0.96 (95% CI, 0.95–0.97) for Authoritative, 0.99 (95% CI, 0.98–1.00) for Authoritarian, and 0.99 (95% CI, 0.99–1.00) for Permissive styles. The corresponding aRRs for persistent nighttime diaper use were 0.93 (95% CI, 0.91–0.95), 0.96 (95% CI, 0.94–0.98), and 0.98 (95% CI, 0.96–1.01). No significant interaction was found with child sex, whereas a significant interaction was observed between child developmental status and Authoritarian style. Conclusions: Maternal parenting styles were associated with nighttime diaper use at age 3 and its persistence at age 4. Although nighttime diaper use is not a direct measure of nocturnal continence, these findings suggest that maternal caregiving context may be relevant to early nighttime diaper discontinuation before school age. Trial Registration: ClinicalTrials.gov identifier: UMIN000030786
- Open Access
- 9 September 2026
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 98 (3)
Association of testicular MRI findings with spermatogenic status and intratesticular sperm in patients with azoospermia or cryptozoospermia
Background: The pathophysiology and presence of intratesticular sperm in patients with azoospermia are usually assessed based on clinical findings, hormonal evaluation, and ultrasonography; however, assessment based on these conventional examinations does not always yield an accurate diagnosis. Objectives: We focused on magnetic resonance imaging (MRI) and aimed to investigate the association between testicular MRI findings, spermatogenic status, and the presence of intratesticular sperm in patients with azoospermia or cryptozoospermia. Methods: Thirty-three patients (45 testes) who underwent preoperative testicular magnetic resonance imaging (MRI) and intraoperative testicular biopsy during varicocelectomy or testicular sperm extraction were included in this study. Associations between the apparent diffusion coefficient (ADC) values of testes and clinical parameters were analyzed. Results: Among the 33 patients (45 testes) included in the analysis, normalized ADC values showed significant positive correlations with serum follicle-stimulating hormone (FSH) (rs = 0.366, p = 0.015) and LH (rs = 0.414, p = 0.006), and a significant negative correlation with Johnsen’s score count (JSC) (rs = -0.377, p = 0.0088). No significant correlation was observed between ADC values and total testosterone (TT) concentration or testicular volume (TV). ADC values were significantly higher in testes without intratesticular sperm (p < 0.000005). Receiver-operating characteristic (ROC) analysis yielded an area under the curve (AUC) of 0.667 for predicting the presence of intratesticular sperm, using a cutoff ADC value of 0.382×10-3 mm2/s (sensitivity 0.686, specificity 0.8). Conclusions: These findings suggest that testicular MRI findings are associated with spermatogenic status and the presence of intratesticular sperm and may provide complementary information when combined with other clinical parameters.
- 9 September 2026
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 98 (3)
Open AccessAssociation of testicular MRI findings with spermatogenic status and intratesticular sperm in patients with azoospermia or cryptozoospermia
Background: The pathophysiology and presence of intratesticular sperm in patients with azoospermia are usually assessed based on clinical findings, hormonal evaluation, and ultrasonography; however, assessment based on these conventional examinations does not always yield an accurate diagnosis. Objectives: We focused on magnetic resonance imaging (MRI) and aimed to investigate the association between testicular MRI findings, spermatogenic status, and the presence of intratesticular sperm in patients with azoospermia or cryptozoospermia. Methods: Thirty-three patients (45 testes) who underwent preoperative testicular magnetic resonance imaging (MRI) and intraoperative testicular biopsy during varicocelectomy or testicular sperm extraction were included in this study. Associations between the apparent diffusion coefficient (ADC) values of testes and clinical parameters were analyzed. Results: Among the 33 patients (45 testes) included in the analysis, normalized ADC values showed significant positive correlations with serum follicle-stimulating hormone (FSH) (rs = 0.366, p = 0.015) and LH (rs = 0.414, p = 0.006), and a significant negative correlation with Johnsen’s score count (JSC) (rs = -0.377, p = 0.0088). No significant correlation was observed between ADC values and total testosterone (TT) concentration or testicular volume (TV). ADC values were significantly higher in testes without intratesticular sperm (p < 0.000005). Receiver-operating characteristic (ROC) analysis yielded an area under the curve (AUC) of 0.667 for predicting the presence of intratesticular sperm, using a cutoff ADC value of 0.382×10-3 mm2/s (sensitivity 0.686, specificity 0.8). Conclusions: These findings suggest that testicular MRI findings are associated with spermatogenic status and the presence of intratesticular sperm and may provide complementary information when combined with other clinical parameters.
- Open Access
Immunosuppressive Role of Integrin β8 in Recurrence After Bacillus Calmette–Guérin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer
Background: Although immunosuppressive factors contribute to the recurrence of non-muscle invasive bladder cancer (NMIBC) during Bacillus Calmette–Guérin (BCG) therapy, the mechanism remains unclear. Methods: In this study, key players in the immunosuppression associated with recurrence after BCG therapy were identified through comprehensive genetic and functional analyses of untreated NMIBC. Results: Microarray analysis of bladder cancer tissue from 13 eligible NMIBC patients revealed an association between high expression of integrin β8 (ITGB8) and recurrence after BCG treatment (p < 0.001). In UMUC cells exhibiting high ITGB8 expression, ITGB8 knockdown significantly decreased cell growth, invasion, adhesion, and secretion of the immunosuppressive cytokine transforming growth factor-β1 (TGF-β1, p < 0.01 for each). In addition, ITGB8 and TGF-β1 expression were correlated in immunohistochemistry of surgical specimens from 13 patients (p < 0.05). These results indicate that ITGB8 regulates TGF-β1 secretion. Conclusions: ITGB8 may contribute to post-BCG therapy recurrence of NMIBC by suppressing tumor immunity through the activation of TGF-β1. Evaluation of ITGB8 expression in preoperative NMIBC could potentially predict recurrence following intravesical BCG therapy.
Open AccessImmunosuppressive Role of Integrin β8 in Recurrence After Bacillus Calmette–Guérin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer
Background: Although immunosuppressive factors contribute to the recurrence of non-muscle invasive bladder cancer (NMIBC) during Bacillus Calmette–Guérin (BCG) therapy, the mechanism remains unclear. Methods: In this study, key players in the immunosuppression associated with recurrence after BCG therapy were identified through comprehensive genetic and functional analyses of untreated NMIBC. Results: Microarray analysis of bladder cancer tissue from 13 eligible NMIBC patients revealed an association between high expression of integrin β8 (ITGB8) and recurrence after BCG treatment (p < 0.001). In UMUC cells exhibiting high ITGB8 expression, ITGB8 knockdown significantly decreased cell growth, invasion, adhesion, and secretion of the immunosuppressive cytokine transforming growth factor-β1 (TGF-β1, p < 0.01 for each). In addition, ITGB8 and TGF-β1 expression were correlated in immunohistochemistry of surgical specimens from 13 patients (p < 0.05). These results indicate that ITGB8 regulates TGF-β1 secretion. Conclusions: ITGB8 may contribute to post-BCG therapy recurrence of NMIBC by suppressing tumor immunity through the activation of TGF-β1. Evaluation of ITGB8 expression in preoperative NMIBC could potentially predict recurrence following intravesical BCG therapy.
- Open Access
- 18 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (8) , 467
Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer
Since cancer is often linked to the aging process, the importance of cellular senescence in cancer has come under the spotlight. While senescence in cancer cells can serve as a natural barrier against cancer due to its proliferation arrest, its secretory phenotypes and alterations in the surface proteome can paradoxically promote or suppress tumor progression. Senescent cancer-associated fibroblasts, endothelial cells, and immune cells can also contribute to cancer promotion. During therapeutic interventions for cancer, not only their therapeutic effects, but also therapy-induced senescence may have an impact on cancer outcomes. Senotherapeutics, therapy targeting senescent cells, have been reported as novel cancer therapy in recent studies, and the combination of senescence induction and senotherapeutics has been increasingly recognized. Although some clinical trials of senotherapeutic drugs for cancer with or without senescence-inducible therapy are ongoing, there is as yet no satisfactory clinical application. With further research into targeting senescence in oncology, it is expected that senotherapeutics, particularly in combination with senescence-inducing therapy, will become a novel therapeutic strategy.
- 18 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (8) , 467
Open AccessTargeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer
Since cancer is often linked to the aging process, the importance of cellular senescence in cancer has come under the spotlight. While senescence in cancer cells can serve as a natural barrier against cancer due to its proliferation arrest, its secretory phenotypes and alterations in the surface proteome can paradoxically promote or suppress tumor progression. Senescent cancer-associated fibroblasts, endothelial cells, and immune cells can also contribute to cancer promotion. During therapeutic interventions for cancer, not only their therapeutic effects, but also therapy-induced senescence may have an impact on cancer outcomes. Senotherapeutics, therapy targeting senescent cells, have been reported as novel cancer therapy in recent studies, and the combination of senescence induction and senotherapeutics has been increasingly recognized. Although some clinical trials of senotherapeutic drugs for cancer with or without senescence-inducible therapy are ongoing, there is as yet no satisfactory clinical application. With further research into targeting senescence in oncology, it is expected that senotherapeutics, particularly in combination with senescence-inducing therapy, will become a novel therapeutic strategy.
- Open Access
- 28 May 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (4) , 419-422
Combination of Neoadjuvant Gemcitabine‐Cisplatin and Anti‐Tuberculosis Therapy for a Patient With Muscle‐Invasive Bladder Cancer and Renal Granulomatosis That Progressed After Intravesical Bacillus Calmette‐Guérin Therapy
Introduction: A case of muscle‐invasive bladder cancer and renal granulomatosis that developed after intravesical Bacillus Calmette‐Guérin therapy, in which a combination of neoadjuvant gemcitabine‐cisplatin and anti‐tuberculosis therapy was safely administered, and radical cystectomy was ultimately performed, is reported.Case Presentation: A 64‐year‐old man with non‐muscle‐invasive bladder cancer underwent transurethral resection and intravesical Bacillus Calmette‐Guérin therapy every time bladder cancer recurred. However, the patient developed left renal granulomatosis during treatment. Anti‐tuberculosis therapy was prioritized since there was no bladder cancer progression. However, local bladder cancer progression was observed during the anti‐tuberculosis therapy. To successfully cure the renal granulomatosis and suppress tumor progression, neoadjuvant gemcitabine‐cisplatin was combined with anti‐tuberculosis therapy for 2 months, followed by radical cystectomy. There were no gemcitabine‐cisplatin complications and no renal granulomatosis recurrence during combination therapy.Conclusion: Combination of gemcitabine‐cisplatin and anti‐tuberculosis therapy was possible for a patient with bladder cancer when Bacillus Calmette‐Guérin infection was under control.
- 28 May 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (4) , 419-422
Open AccessCombination of Neoadjuvant Gemcitabine‐Cisplatin and Anti‐Tuberculosis Therapy for a Patient With Muscle‐Invasive Bladder Cancer and Renal Granulomatosis That Progressed After Intravesical Bacillus Calmette‐Guérin Therapy
Introduction: A case of muscle‐invasive bladder cancer and renal granulomatosis that developed after intravesical Bacillus Calmette‐Guérin therapy, in which a combination of neoadjuvant gemcitabine‐cisplatin and anti‐tuberculosis therapy was safely administered, and radical cystectomy was ultimately performed, is reported.Case Presentation: A 64‐year‐old man with non‐muscle‐invasive bladder cancer underwent transurethral resection and intravesical Bacillus Calmette‐Guérin therapy every time bladder cancer recurred. However, the patient developed left renal granulomatosis during treatment. Anti‐tuberculosis therapy was prioritized since there was no bladder cancer progression. However, local bladder cancer progression was observed during the anti‐tuberculosis therapy. To successfully cure the renal granulomatosis and suppress tumor progression, neoadjuvant gemcitabine‐cisplatin was combined with anti‐tuberculosis therapy for 2 months, followed by radical cystectomy. There were no gemcitabine‐cisplatin complications and no renal granulomatosis recurrence during combination therapy.Conclusion: Combination of gemcitabine‐cisplatin and anti‐tuberculosis therapy was possible for a patient with bladder cancer when Bacillus Calmette‐Guérin infection was under control.
- Open Access
- 23 January 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (2) , 154-157
Late solitary metastasis of chromophobe renal cell carcinoma in the residual ureter
Introduction: Postoperative recurrence of chromophobe renal cell carcinoma is rare, and its metastatic process remains unclear. We here report a case of a solitary metastasis in the residual ureter detected 9 years after the primary surgery and discuss its possible recurrence mechanism based on our immunohistochemical study.Case presentation: A 67‐year‐old woman received nephrectomy for a left renal tumor, which was diagnosed as chromophobe renal cell carcinoma with urinary collecting system invasion. Nine years postoperatively, a tumor was found in the residual ureteral stump and was surgically excised. The recurrent tumor was histologically diagnosed as chromophobe renal cell carcinoma surrounded by normal urothelial cells. On immunohistochemical staining, the tumor cells showed a high expression of uroplakin‐2, a urothelium‐specific marker.Conclusion: In our case, highly adhesive uroplakin‐2‐positive cancer cells spilled from the primary site and attached to the residual ureteral stump, growing slowly while being gradually covered by normal urothelial cells.
- 23 January 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (2) , 154-157
Open AccessLate solitary metastasis of chromophobe renal cell carcinoma in the residual ureter
Introduction: Postoperative recurrence of chromophobe renal cell carcinoma is rare, and its metastatic process remains unclear. We here report a case of a solitary metastasis in the residual ureter detected 9 years after the primary surgery and discuss its possible recurrence mechanism based on our immunohistochemical study.Case presentation: A 67‐year‐old woman received nephrectomy for a left renal tumor, which was diagnosed as chromophobe renal cell carcinoma with urinary collecting system invasion. Nine years postoperatively, a tumor was found in the residual ureteral stump and was surgically excised. The recurrent tumor was histologically diagnosed as chromophobe renal cell carcinoma surrounded by normal urothelial cells. On immunohistochemical staining, the tumor cells showed a high expression of uroplakin‐2, a urothelium‐specific marker.Conclusion: In our case, highly adhesive uroplakin‐2‐positive cancer cells spilled from the primary site and attached to the residual ureteral stump, growing slowly while being gradually covered by normal urothelial cells.
- Open Access
- 23 January 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-9
Longitudinal changes in factors affecting postoperative patient satisfaction after robot-assisted radical prostatectomy: an assessment using a patient-reported questionnaire
Long-term survival can be achieved in patients with localized prostate cancer (PCa). Therefore, maintenance of postoperative quality of life (QOL) and treatment satisfaction are important. Although longitudinal changes in disease-specific QOL are reported, there are few studies investigating which factors longitudinally affect treatment satisfaction in patients who undergo robot-assisted radical prostatectomy (RARP). Therefore, we examined the factors associated with treatment satisfaction over the first 12 months postoperatively based on an assessment using a patient-reported questionnaire. Of the 612 consecutive patients who underwent RARP, 408 patients were enrolled in this study and divided into a satisfied group and a non-satisfied group at every evaluation timepoint. Multivariate logistic regression analysis was conducted to clarify factors affecting the postoperative treatment satisfaction between the two groups. Multivariate logistic regression analysis revealed that factors relating to treatment satisfaction had longitudinally changed. Urinary bother (UB) (odds ratio (OR) = 1.023; p = 0.008), and sexual function (SF) (OR = 0.941; p = 0.004) were the significant factors associated with treatment satisfaction at 1 month postoperatively; UB (OR = 1.040; p = 0.001) and sexual bother (SB) (OR = 1.019; p < 0.001) at 3 months; urinary function (UF) (OR = 1.027; p = 0.008), UB (OR = 1.035; p = 0.011), SB (OR = 1.013; p = 0.009), and hormonal bother (HB) (OR = 1.065; p = 0.023) at 6 months; UF (OR = 1.026; p = 0.008), UB (OR = 1.030; p = 0.029), and SB (OR = 1.014; p = 0.004) at 9 months; UF (OR = 1.024; p = 0.002) at 12 months. Treatment satisfaction in patients who underwent RARP changed over time. Our results suggest that giving sufficient information before treatment choice is both important and useful for patients’ decision-making, leading to improved patient QOL.
- 23 January 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-9
Open AccessLongitudinal changes in factors affecting postoperative patient satisfaction after robot-assisted radical prostatectomy: an assessment using a patient-reported questionnaire
Long-term survival can be achieved in patients with localized prostate cancer (PCa). Therefore, maintenance of postoperative quality of life (QOL) and treatment satisfaction are important. Although longitudinal changes in disease-specific QOL are reported, there are few studies investigating which factors longitudinally affect treatment satisfaction in patients who undergo robot-assisted radical prostatectomy (RARP). Therefore, we examined the factors associated with treatment satisfaction over the first 12 months postoperatively based on an assessment using a patient-reported questionnaire. Of the 612 consecutive patients who underwent RARP, 408 patients were enrolled in this study and divided into a satisfied group and a non-satisfied group at every evaluation timepoint. Multivariate logistic regression analysis was conducted to clarify factors affecting the postoperative treatment satisfaction between the two groups. Multivariate logistic regression analysis revealed that factors relating to treatment satisfaction had longitudinally changed. Urinary bother (UB) (odds ratio (OR) = 1.023; p = 0.008), and sexual function (SF) (OR = 0.941; p = 0.004) were the significant factors associated with treatment satisfaction at 1 month postoperatively; UB (OR = 1.040; p = 0.001) and sexual bother (SB) (OR = 1.019; p < 0.001) at 3 months; urinary function (UF) (OR = 1.027; p = 0.008), UB (OR = 1.035; p = 0.011), SB (OR = 1.013; p = 0.009), and hormonal bother (HB) (OR = 1.065; p = 0.023) at 6 months; UF (OR = 1.026; p = 0.008), UB (OR = 1.030; p = 0.029), and SB (OR = 1.014; p = 0.004) at 9 months; UF (OR = 1.024; p = 0.002) at 12 months. Treatment satisfaction in patients who underwent RARP changed over time. Our results suggest that giving sufficient information before treatment choice is both important and useful for patients’ decision-making, leading to improved patient QOL.
- Open Access
- 21 October 2024
- Published by Wiley in IJU Case Reports
- Vol. 8 (1) , 36-40
Vogt‐Koyanagi‐Harada disease‐like uveitis induced by nivolumab in metastatic renal cell carcinoma
Introduction: Nivolumab can cause various immune‐related adverse events; it rarely induces Vogt‐Koyanagi‐Harada‐disease‐like uveitis. Vogt‐Koyanagi‐Harada‐disease is reported to be closely associated with human leukocyte antigen‐DR4.Case presentation: A 68‐year‐old man with metastatic renal cancer underwent nephrectomy. Computed tomography showed multiple lung tumors, raising suspicion of lung metastases. However, one lung hilar mass was suspected to be primary lung cancer, leading to a lobectomy, which subsequently revealed lung metastases of renal cancer. The patient underwent nivolumab treatment but developed Vogt‐Koyanagi‐Harada‐disease‐like uveitis as an immune‐related adverse event. Human leukocyte antigen‐DR4 alleles were identified, and the uveitis improved with topical steroids. He maintained partial response of lung metastases after nivolumab resumption. Immunohistochemical staining revealed significantly higher human leukocyte antigen‐DR4 expression in lung metastasis than primary renal cancer.Conclusion: Despite inducing Vogt‐Koyanagi‐Harada‐disease‐like uveitis, nivolumab controlled cancer progression effectively. Immunohistochemical staining results suggest the potential involvement of human leukocyte antigen‐DR4 expression in both the onset of Vogt‐Koyanagi‐Harada‐disease‐like uveitis and nivolumab efficacy.
- 21 October 2024
- Published by Wiley in IJU Case Reports
- Vol. 8 (1) , 36-40
Open AccessVogt‐Koyanagi‐Harada disease‐like uveitis induced by nivolumab in metastatic renal cell carcinoma
Introduction: Nivolumab can cause various immune‐related adverse events; it rarely induces Vogt‐Koyanagi‐Harada‐disease‐like uveitis. Vogt‐Koyanagi‐Harada‐disease is reported to be closely associated with human leukocyte antigen‐DR4.Case presentation: A 68‐year‐old man with metastatic renal cancer underwent nephrectomy. Computed tomography showed multiple lung tumors, raising suspicion of lung metastases. However, one lung hilar mass was suspected to be primary lung cancer, leading to a lobectomy, which subsequently revealed lung metastases of renal cancer. The patient underwent nivolumab treatment but developed Vogt‐Koyanagi‐Harada‐disease‐like uveitis as an immune‐related adverse event. Human leukocyte antigen‐DR4 alleles were identified, and the uveitis improved with topical steroids. He maintained partial response of lung metastases after nivolumab resumption. Immunohistochemical staining revealed significantly higher human leukocyte antigen‐DR4 expression in lung metastasis than primary renal cancer.Conclusion: Despite inducing Vogt‐Koyanagi‐Harada‐disease‐like uveitis, nivolumab controlled cancer progression effectively. Immunohistochemical staining results suggest the potential involvement of human leukocyte antigen‐DR4 expression in both the onset of Vogt‐Koyanagi‐Harada‐disease‐like uveitis and nivolumab efficacy.
- Open Access
- 29 August 2024
- Published by Wiley in IJU Case Reports
- Vol. 7 (6) , 438-441
Urodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T‐cell leukemia virus type I‐associated myelopathy/tropical spastic paraparesis
Introduction: Human T‐cell lymphotropic virus type 1 infection can cause HTLV‐1‐associated myelopathy/tropical spastic paraparesis, characterized by spastic paralysis of both lower limbs. More than 90% of HAM/TSP patients show lower urinary tract symptoms and dysfunction.Case presentation: A 27‐year‐old woman diagnosed with HAM/TSP presented with overactive bladder. A urodynamic study revealed detrusor overactivity. OAB remained despite improvements in spastic paralysis of the lower limbs after starting prednisolone. The addition of solifenacin likewise failed to improve OAB or DO in this patient. Switching from solifenacin to vibegron improved OAB symptoms.Conclusion: In patients for whom OAB and DO do not improve with steroid treatment and solifenacin, treatment with vibegron may improve OAB symptoms.
- 29 August 2024
- Published by Wiley in IJU Case Reports
- Vol. 7 (6) , 438-441
Open AccessUrodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T‐cell leukemia virus type I‐associated myelopathy/tropical spastic paraparesis
Introduction: Human T‐cell lymphotropic virus type 1 infection can cause HTLV‐1‐associated myelopathy/tropical spastic paraparesis, characterized by spastic paralysis of both lower limbs. More than 90% of HAM/TSP patients show lower urinary tract symptoms and dysfunction.Case presentation: A 27‐year‐old woman diagnosed with HAM/TSP presented with overactive bladder. A urodynamic study revealed detrusor overactivity. OAB remained despite improvements in spastic paralysis of the lower limbs after starting prednisolone. The addition of solifenacin likewise failed to improve OAB or DO in this patient. Switching from solifenacin to vibegron improved OAB symptoms.Conclusion: In patients for whom OAB and DO do not improve with steroid treatment and solifenacin, treatment with vibegron may improve OAB symptoms.
- Open Access
- 31 January 2024
- Published by Wiley in IJU Case Reports
- Vol. 7 (3) , 197-200
CHARGE syndrome with both primary and secondary hypogonadism
Introduction CHARGE syndrome is a rare disorder that causes congenital abnormalities in multiple organs, including secondary hypogonadism. We report, herein, a unique case of CHARGE syndrome with both primary and secondary hypogonadism and discuss the possible causes and pathogenesis in this patient. Case presentation A 15-year-old boy with delayed secondary sexual characteristics and non-palpable testes was referred to our hospital. Physical examination and detection of a chromodomain-helicase-deoxyribonucleic acid-binding protein 7 gene mutation confirmed CHARGE syndrome. Hormone stimulation tests suggested both primary and secondary hypogonadism. Laparoscopic bilateral orchiectomy was performed because of decreased testosterone production and atrophy in both testes. Pathological examination of the testes revealed maturation arrest, germ cell neoplasm in situ, and decreased expression of steroid synthase. Conclusion This appears to be the first report of CHARGE syndrome with both primary and secondary hypogonadism demonstrated in endocrinological and histological examinations.
- 31 January 2024
- Published by Wiley in IJU Case Reports
- Vol. 7 (3) , 197-200
Open AccessCHARGE syndrome with both primary and secondary hypogonadism
Introduction CHARGE syndrome is a rare disorder that causes congenital abnormalities in multiple organs, including secondary hypogonadism. We report, herein, a unique case of CHARGE syndrome with both primary and secondary hypogonadism and discuss the possible causes and pathogenesis in this patient. Case presentation A 15-year-old boy with delayed secondary sexual characteristics and non-palpable testes was referred to our hospital. Physical examination and detection of a chromodomain-helicase-deoxyribonucleic acid-binding protein 7 gene mutation confirmed CHARGE syndrome. Hormone stimulation tests suggested both primary and secondary hypogonadism. Laparoscopic bilateral orchiectomy was performed because of decreased testosterone production and atrophy in both testes. Pathological examination of the testes revealed maturation arrest, germ cell neoplasm in situ, and decreased expression of steroid synthase. Conclusion This appears to be the first report of CHARGE syndrome with both primary and secondary hypogonadism demonstrated in endocrinological and histological examinations.